Your browser doesn't support javascript.
loading
Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
Abdel Malek, Mohamed A Y; Jagannathan, Sajjeev; Malek, Ehsan; Sayed, Douaa M; Elgammal, Sahar A; Abd El-Azeem, Hanan G; Thabet, Nabila M; Driscoll, James J.
Afiliación
  • Abdel Malek MA; The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Jagannathan S; Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Malek E; Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.
  • Sayed DM; The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Elgammal SA; Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Abd El-Azeem HG; The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Thabet NM; Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Driscoll JJ; Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Oncotarget ; 6(5): 3098-110, 2015 Feb 20.
Article en En | MEDLINE | ID: mdl-25605012
Despite the clinical benefit of the proteasome inhibitor bortezomib, multiple myeloma (MM) patients invariably relapse through poorly defined mechanisms. Myeloma cells inevitably develop chemoresistance that leads to disease relapse and patient-related deaths. Studies in tumor cell lines and biopsies obtained from patients refractory to therapy have revealed that myeloma cells adapt to stress by inducing expression of glucose-regulated protein 78 (GRP78), an endoplasmic reticulum (ER) chaperone with anti-apoptotic properties. Treatment of myeloma cells with bortezomib increased GRP78 levels and activated GRP78-dependent autophagy. Expression profiling indicated that GRP78-encoding HSPA5 was significantly upregulated in bortezomib-resistant cells. Co-treatment with the anti-diabetic agent metformin suppressed GRP78 and enhanced the anti-proliferative effect of bortezomib. Bortezomib treatment led to GRP78 co-localization with proteotoxic protein aggregates, known as aggresomes. Pharmacologic suppression, genetic ablation or mutational inactivation of GRP78 followed by bortezomib treatment led to the accumulation of aggresomes but impaired autophagy and enhanced anti-myeloma effect of bortezomib. GRP78 was co-immunoprecipitated with the KDEL receptor, an ER quality control regulator that binds proteins bearing the KDEL motif to mediate their retrieval from the Golgi complex back to the ER. Taken together, we demonstrate that inhibition of GRP78 functional activity disrupts autophagy and enhances the anti-myeloma effect of bortezomib.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Autofagia / Orgánulos / Resistencia a Antineoplásicos / Inhibidores de Proteasoma / Bortezomib / Proteínas de Choque Térmico / Mieloma Múltiple / Antineoplásicos Límite: Humans Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Autofagia / Orgánulos / Resistencia a Antineoplásicos / Inhibidores de Proteasoma / Bortezomib / Proteínas de Choque Térmico / Mieloma Múltiple / Antineoplásicos Límite: Humans Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos